Hasil Pencarian - Jacqueline C. Barrientos

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

    Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia oleh Matthew Kaufman, Xiao-Jie Yan, Wentian Li, Emanuela M. Ghia, Anton W. Langerak, Laura Z. Rassenti, Chrysoula Belessi, Neil E. Kay, Frederic Davi, John C. Byrd, Sarka Pospisilova, Jennifer R. Brown, Mark Catherwood, Zadie Davis, David Oscier, Marco Montillo, Livio Trentin, Richard Rosenquist, Paolo Ghia, Jacqueline C. Barrientos, Jacqueline C. Barrientos, Jacqueline C. Barrientos, Jacqueline C. Barrientos, Jonathan E. Kolitz, Jonathan E. Kolitz, Steven L. Allen, Steven L. Allen, Kanti R. Rai, Kanti R. Rai, Kanti R. Rai, Kanti R. Rai, Kostas Stamatopoulos, Thomas J. Kipps, Donna Neuberg, Nicholas Chiorazzi, Nicholas Chiorazzi, Nicholas Chiorazzi, Nicholas Chiorazzi

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice

    A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice oleh Piers E. M. Patten, Piers E. M. Patten, Gerardo Ferrer, Shih-Shih Chen, Jonathan E. Kolitz, Jonathan E. Kolitz, Kanti R. Rai, Kanti R. Rai, Steven L. Allen, Steven L. Allen, Jacqueline C. Barrientos, Jacqueline C. Barrientos, Nikolaos Ioannou, Alan G. Ramsay, Nicholas Chiorazzi, Nicholas Chiorazzi, Nicholas Chiorazzi

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis

    First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pool... oleh Paolo Ghia, Carolyn Owen, John N. Allan, Jacqueline C. Barrientos, Paul M. Barr, Chunxue Shi, Anita Szoke, Christopher Abbazio, Gabriel S. Krigsfeld, Jan A. Burger

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

    Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial oleh Paolo Ghia, Steven E. Coutre, Bruce D. Cheson, Jacqueline C. Barrientos, Peter Hillmen, Andrew R. Pettitt, Andrew D. Zelenetz, Sanatan Shreay, Michael Hallek, Richard R. Furman

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

    Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial oleh Marco Montillo, Árpád Illés, Tadeusz Robak, Alexander S. Pristupa, Malgorzata Wach, Miklós Egyed, Julio Delgado, Wojciech Jurczak, Franck Morschhauser, Anna Schuh, Herbert Eradat, Sanatan Shreay, Jacqueline C. Barrientos, Andrew D. Zelenetz

    Diterbitkan 2019-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course

    Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course oleh Davide Bagnara, Davide Bagnara, Catherine Tang, Jennifer R. Brown, Siddha Kasar, Stacey Fernandes, Monica Colombo, Stefano Vergani, Andrea N. Mazzarello, Fabio Ghiotto, Fabio Ghiotto, Silvia Bruno, Fortunato Morabito, Fortunato Morabito, Kanti R. Rai, Kanti R. Rai, Jonathan E. Kolitz, Jonathan E. Kolitz, Jacqueline C. Barrientos, Jacqueline C. Barrientos, Steven L. Allen, Steven L. Allen, Franco Fais, Franco Fais, Matthew D. Scharff, Thomas MacCarthy, Nicholas Chiorazzi, Nicholas Chiorazzi

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Activated CLL cells regulate IL-17F–producing Th17 cells in miR155-dependent and outcome-specific manners

    Activated CLL cells regulate IL-17F–producing Th17 cells in miR155-dependent and outcome-specific manners oleh Byeongho Jung, Gerardo Ferrer, Pui Yan Chiu, Rukhsana Aslam, Anita Ng, Florencia Palacios, Michael Wysota, Martina Cardillo, Jonathan E. Kolitz, Steven L. Allen, Jacqueline C. Barrientos, Kanti R. Rai, Nicholas Chiorazzi, Barbara Sherry

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

    Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia oleh Steven E. Coutre, Ian W. Flinn, Sven de Vos, Jacqueline C. Barrientos, Marshall T. Schreeder, Nina D. Wagner-Johnson, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Lyndah Dreiling, Yeonhee Kim, Siddhartha Mitra, Kanti Rai, John P. Leonard, Richard R. Furman

    Diterbitkan 2018-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

    Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma oleh Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard

    Diterbitkan 2016-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

    Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia oleh Farhad Ravandi, Robert J. Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sasha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Jeffrey Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Philip A. Thompson, Xavier Troussard, Clive S. Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann, Kanti Rai, Michael Grever

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: